EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review

Erfan Taherifard iD, Krystal Tran, Ali Saeed, Jehad Amer Yasin iD, Anwaar Saeed

Diagnostics · 16.09.2024 · 14 (18) · 2054

DOI: 10.3390/diagnostics14182054 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 16.09.2024. Verfasst von Erfan Taherifard und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), the most common primary liver malignancy and the sixth most common cancer globally, remains fatal for many patients with inappropriate responses to treatment. Recent advancements in immunotherapy have transformed the treatment landscape for advanced HCC. However, variability in patient responses to immunotherapy highlights the need for biomarkers that can predict treatment outcomes. This manuscript comprehensively reviews the evolving role of biomarkers in immunotherapy efficacy, spanning from blood-derived indicators—alpha-fetoprotein, inflammatory markers, cytokines, circulating tumor cells, and their DNA—to tissue-derived indicators—programmed cell death ligand 1 expression, tumor mutational burden, microsatellite instability, and tumor-infiltrating lymphocytes. The current body of evidence suggests that these biomarkers hold promise for improving patient selection and predicting immunotherapy outcomes. Each biomarker offers unique insights into disease biology and the immune landscape of HCC, potentially enhancing the precision of treatment strategies. However, challenges such as methodological variability, high costs, inconsistent findings, and the need for large-scale validation in well-powered two-arm trial studies persist, making them currently unsuitable for integration into standard care. Addressing these challenges through standardized techniques and implementation of further studies will be critical for the future incorporation of these biomarkers into clinical practice for advanced HCC.

Schlagwörter

Stichwörter der Autor:innen

alpha-fetoproteinsbiomarkerscirculating neoplastic cellscirculating tumor DNAcytokineshepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapymicrosatellite instabilityprogrammed cell death 1programmed cell death ligand 1tumor-infiltrating lymphocytes

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA 15232, USA.
  • Department of Medicine, Ochsner Lafayette General Medical Center, Lafayette, LA 70503, USA.
  • UPMC Hillman Cancer Center, Pittsburgh, PA 15232, USA.

ORCID-Profile: Erfan Taherifard, Jehad Amer Yasin

Zitieren

APA

Taherifard, E., Tran, K., Saeed, A., Yasin, J. A., & Saeed, A. (2024). Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review. Diagnostics, 14(18), 2054. https://doi.org/10.3390/diagnostics14182054

Vancouver

Taherifard E, Tran K, Saeed A, Yasin JA, Saeed A. Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review. Diagnostics. 2024;14(18):2054. doi:10.3390/diagnostics14182054

BibTeX
@article{Taherifard2024,
  author = {Taherifard, Erfan and Tran, Krystal and Saeed, Ali and Yasin, Jehad Amer and Saeed, Anwaar},
  title = {Biomarkers for Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma: A Comprehensive Review},
  journal = {Diagnostics},
  year = {2024},
  volume = {14},
  number = {18},
  pages = {2054},
  doi = {10.3390/diagnostics14182054}
}
Kostenlos starten →